Skin boosters and polynucleotides, training and the legal line

Last reviewed: 30 July 2026.

Who wrote this: Aurelia Institute trains healthcare professionals in medical aesthetics, so we have a commercial interest in this subject. We are not currently running these courses and hold no awarding organisation approval. This page is a guide, not a course for sale, and it is not clinical or legal advice.

Skin boosters, polynucleotides and exosomes are frequently taught on the same day, marketed in the same sentence and grouped under the same heading. They sit on completely different legal footings, and the difference is the single most important thing a practitioner in this area needs to understand.

Polynucleotide products marketed in the UK have a regulatory route. Injectable exosomes do not. Practitioners are injecting exosomes across the UK, and doing so puts them outside the law, outside their insurance and inside the MHRA’s area of interest.

This page covers what these treatments are, where each one sits legally, what training should teach, and what to ask a provider who groups them together.

The short version

Treatment	What it is	UK position
Hyaluronic acid skin boosters	Low cross-linked HA injected for hydration and skin quality	Regulated as medical devices. Established route.
Polynucleotides	PN and PDRN preparations, commonly salmon or trout derived	Products marketed in the UK carry a device route. Established.
Exosomes, injected	Extracellular vesicles	No UK marketing authorisation. Injecting is not lawful.
Exosomes, topical	Applied to skin, often after microneedling	The only route currently used lawfully in the UK.

The exosome problem, stated plainly

The MHRA’s position, reported consistently across UK sources including the Save Face register and aesthetic insurers, is that injectable exosome preparations are medicinal products, and no exosome injectable holds a UK marketing authorisation.

The consequence follows directly. Administering an unlicensed medicinal product by injection for cosmetic purposes is not lawful, and no amount of consent from the patient changes that. Topical application, typically alongside microneedling, is the route currently used in the UK.

If you are being taught to inject exosomes, or sold them for injection, several things are true at once. You are outside the licensing framework. Your insurer is unlikely to cover you, because policies generally exclude unlicensed products. And the patient is receiving something whose safety and efficacy have not been assessed by any UK regulator.

Because this is a live and moving area, verify the current position with the MHRA directly before making a decision either way rather than relying on a training provider, an aesthetics supplier, or this page. Suppliers have a commercial interest in the answer, and some are more comfortable with ambiguity than the law is.

That caution is worth extending to anyone teaching this. A course that presents injectable exosomes as a normal treatment option is telling you something useful about the provider.

Polynucleotides are a different case

Polynucleotides, and polydeoxyribonucleotide preparations, are the fastest growing part of this category and they sit on a different footing. Products marketed in the UK such as the well known salmon and trout derived preparations have a regulatory route as devices, and practitioners using them are working inside the framework rather than outside it.

What training should cover, beyond technique:

What the product actually is. Purified nucleotide fragments, typically from fish sources, which has an obvious consequence for patients with fish allergy that needs to be a screening question rather than an afterthought.

Where it sits against filler. These are not volumising products. A patient expecting the change a cheek filler produces will be disappointed by a skin booster, and managing that expectation is the whole consultation.

Course structure. These treatments are delivered as a course with maintenance, not as a single appointment. The commercial and consent conversation has to reflect that from the first visit.

Placement and technique. Depth and distribution differ from filler, and from each other between products. Bolus, linear and microdroplet approaches suit different preparations.

Hyaluronic acid skin boosters

The established member of the family and the most straightforward. Low cross-linked hyaluronic acid, injected to improve hydration and skin quality rather than to add structure.

Regulated as medical devices, like other HA fillers. The technique is different from volumising work, the products behave differently, and the results are subtler, which again makes the consultation the difficult part rather than the injection.

Worth noting that hyaluronidase remains relevant. These are hyaluronic acid products, so they can be dissolved, and the same vascular considerations apply where you are injecting into vascular territory.

What good training in this area looks like

Because the category is commercially hot and regulation is uneven, training quality varies more than in most areas.

A course worth taking will tell you the regulatory status of each product it teaches, by name, and will be comfortable saying that one of them cannot lawfully be injected. It will separate the products rather than presenting them as interchangeable skin quality treatments. It will be honest that the evidence base is thinner and younger than for toxin and filler. And it will spend real time on the consultation, because these are treatments where a patient’s expectation is the main determinant of satisfaction.

A course that will not name the regulatory position of what it teaches is a course to walk away from.

Where the evidence sits

More honest than most marketing in this area allows.

Hyaluronic acid skin boosters have a reasonable and reasonably long track record for skin hydration and quality. Polynucleotide preparations have a growing evidence base and generally favourable early reports, with the usual caveat that much of the published work is small, short and sometimes industry linked. Injectable exosomes have insufficient evidence to have satisfied any regulator, which is precisely why no product holds a UK authorisation.

For consultations, the useful framing is that these treatments improve skin quality gradually over a course, that results are subtler than filler, and that maintenance is part of the plan rather than a failure of the first round.

Insurance

Insurers cover named treatments. Skin boosters and polynucleotides are generally coverable with appropriate training.

Unlicensed products are a different matter, and policies commonly exclude them. If you are considering anything in the exosome category, ask your insurer in writing, name the product, and keep the answer. An assurance from a supplier is not cover.

Our guide to what insurers actually ask for covers the questions they put more generally.

What to check before booking

1. Which specific products are taught, by brand name?
2. What is the regulatory status of each, and will the provider state it plainly?
3. Does the course teach injectable exosomes, and if so, on what basis?
4. Is fish allergy screening covered for polynucleotide products?
5. How many live models will you treat, and with which products?
6. Does the course cover the consultation and expectation setting, or only technique?
7. Will your insurer cover each product taught?
8. Does the provider also supply the product, and how does that shape the advice?

Question three is the one that tells you most about the course.

What it costs

Training in this area sits below injectables in course price. The recurring cost is product, and these are course-based treatments, so your cost per patient is the product across a course rather than per session.

Price the course of treatment rather than the appointment, make that clear to the patient at the consultation, and be careful about package deals that commit you to delivering treatments months ahead, because money taken for treatment not yet given is money you may have to return.

Where you can train

Training and local information by city: London, Manchester, Birmingham, Leeds, Glasgow, Edinburgh, Bristol, Liverpool, Cardiff, Newcastle.

Frequently asked questions

Are exosome injections legal in the UK?

No. Injectable exosome preparations are treated as medicinal products and none holds a UK marketing authorisation, so administering them by injection is not lawful. Topical application, often alongside microneedling, is the route used in the UK. Verify the current position with the MHRA before making any decision, as this area is moving.

Are polynucleotides legal in the UK?

Polynucleotide products marketed in the UK have a regulatory route as devices, which places them on a different footing from injectable exosomes. Confirm the status of the specific product you intend to use.

What is the difference between a skin booster and a dermal filler?

Skin boosters use low cross-linked hyaluronic acid to improve hydration and skin quality. Fillers are cross-linked to add volume and structure. Patients expecting the visible change of a filler will be disappointed by a booster.

Do I need a prescriber for skin boosters or polynucleotides?

Products regulated as devices do not require a prescription, unlike botulinum toxin. That is a reason these treatments appeal to non-prescribing practitioners.

Can polynucleotides be dissolved like filler?

Polynucleotides are not hyaluronic acid, so hyaluronidase does not act on them in the way it does on HA products. Hyaluronic acid skin boosters can be dissolved.

Is fish allergy a contraindication for polynucleotides?

Common polynucleotide preparations are derived from fish sources, so allergy screening should be part of the consultation. Check the specific product’s information.

Will my insurance cover exosome treatments?

Policies commonly exclude unlicensed products. Ask your insurer in writing, naming the product, and keep the answer. A supplier’s assurance is not insurance cover.

Does Aurelia Institute run skin booster courses?

Not at present, and we hold no awarding organisation approval. This page exists as a guide.

Sources

• Medicines and Healthcare products Regulatory Agency, on the regulation of medicinal products and marketing authorisation requirements.
• Save Face, patient safety guidance on exosome therapy in the UK.
• Aesthetic insurance guidance on unlicensed products and cover exclusions.
• Provider course outlines and product information, reviewed 30 July 2026.

Regulatory positions in this area are moving. Confirm the status of any specific product with the MHRA and your insurer before offering it.